HOUSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has relocated its corporate operations within the Texas Medical Center in Houston. In addition to new corporate offices, Salarius has opened a new laboratory space in Johnson & Johnson's JLABS @ TMC where Salarius will pursue internal preclinical research and explore new development paths for seclidemstat, the company’s clinical-stage investigational drug candidate.

“We are excited to announce the move into our new corporate offices as we continue to grow as a company and expand our research and development capabilities,” said David Arthur, Chief Executive Officer of Salarius Pharmaceuticals. “Our new corporate offices, in particular, the dedicated internal laboratory operations, will allow Salarius to optimize seclidemstat’s development path more innovatively and efficiently, and ultimately help Salarius achieve its goal of positively impacting patients' lives. The Salarius scientific team can also explore additional drug technologies that could expand our position as one of the leading companies in the field of epigenetic oncology.”

Seclidemstat is a reversible LSD1 inhibitor currently being studied in a Phase 1/2 clinical trial for Ewing sarcoma, a rare and deadly pediatric bone cancer for which there are no approved targeted therapies available. A second Phase 1/2 clinical trial is also underway in advanced solid tumors (AST).

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, or epigenetic causes of cancers, and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for a number of cancers, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers.